Repatha Storage, Stability and Shelf Life: What Every Prescriber and Patient Must Know

What Are the FDA-Approved Storage Conditions for Repatha?

The FDA-approved Repatha prescribing information specifies refrigeration at 2°C to 8°C as the primary storage condition, with a 30-day allowance at room temperature not exceeding 25°C. These conditions apply to all three commercially available presentations: the 140 mg SureClick autoinjector, the 140 mg prefilled syringe, and the 420 mg Pushtronex on-body infusor cartridge.

The prescribing information is the controlling document for storage requirements. It reflects the stability data Amgen submitted to the FDA during the Biologics License Application review process, which evaluated the drug across the International Council for Harmonisation (ICH) Q1A(R2) long-term and accelerated stability testing conditions.

Refrigerated Storage: 2°C to 8°C

Refrigeration at 2°C to 8°C keeps the evolocumab molecule in its most stable conformation. The drug should remain in the original carton during refrigerated storage to protect it from light-induced degradation. Patients using a standard household refrigerator should keep the carton away from the freezer compartment and away from the refrigerator door, where temperature fluctuations during door-opening cycles can push the product toward the upper or lower limits of the acceptable range.

A controlled refrigerator thermometer is advisable for patients who self-inject at home, particularly in warmer climates. Pharmacy dispensing logs and specialty pharmacy cold-chain protocols are governed by USP General Chapter 1079, which defines "cold" as 2°C to 8°C for biologics.

Room-Temperature Excursion: 30 Days at or Below 25°C

Once Repatha is removed from the refrigerator, the 30-day clock starts. The product must be used or discarded within that window, regardless of whether it is returned to the refrigerator afterward. Returning a previously warmed vial or autoinjector to the refrigerator does not reset the stability clock. Patients should write the date of removal on the carton with a marker.

The 30-day room-temperature stability allowance is consistent with data on comparable IgG2 monoclonal antibodies stored under ICH accelerated conditions (25°C / 60% relative humidity). At these conditions, protein oxidation, deamidation of asparagine residues, and aggregation rates increase but remain within specification for approximately one month for most therapeutic antibodies of this class. FDA Repatha prescribing information.

Why Temperature Matters: The Biochemistry of Evolocumab Stability

Evolocumab is a fully human IgG2 monoclonal antibody produced in Chinese hamster ovary cells. Its molecular weight is approximately 144 kDa. Like all therapeutic proteins, its activity depends on maintaining precise three-dimensional folding of the complementarity-determining regions (CDRs) that contact the PCSK9 protein.

Protein Degradation Pathways

Four principal degradation pathways threaten evolocumab outside the recommended storage window.

Aggregation. Elevated temperature accelerates hydrophobic interactions between partially unfolded antibody molecules, producing visible or sub-visible particulate matter. Aggregated protein is both less potent and potentially more immunogenic. Immunogenicity concerns for aggregated biologics are detailed in an FDA guidance document.

Oxidation. Methionine and tryptophan residues in the Fc region are susceptible to oxidation, particularly in the presence of light and elevated temperature. Oxidized variants may show reduced FcRn binding and a shorter half-life in vivo.

Deamidation. Asparagine residues, especially in the CDRs, can deamidated to aspartate under thermal stress, altering the charge profile and potentially reducing antigen-binding affinity.

Fragmentation. Disulfide bond reduction or peptide bond hydrolysis under extreme temperature produces lower-molecular-weight species visible on size-exclusion chromatography, which were assessed as part of Amgen's BLA stability package.

What Happens When Repatha Freezes

Freezing is categorically prohibited. Ice crystal formation physically disrupts the protein tertiary structure. The cryoconcentration effect during thawing pushes local protein concentrations far above specification, driving aggregation. Even a single freeze-thaw cycle can produce irreversible protein aggregation in IgG2 antibodies, rendering the product unsafe to inject. Freeze-thaw effects on therapeutic antibody stability are reviewed in the literature.

Patients should never place Repatha in the freezer, use ice packs that contact the device directly during transport, or store it in a car glove compartment in cold climates where sub-zero temperatures are possible overnight.

How Does Repatha Work? A Brief Mechanism Summary for Context

Understanding why stable, properly stored evolocumab matters requires a short look at its mechanism. Evolocumab binds with high affinity to proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease produced predominantly by hepatocytes. PCSK9 normally binds LDL receptors (LDLR) on the hepatocyte surface and escorts them to lysosomal degradation, reducing the cell's capacity to clear circulating LDL-C.

By blocking PCSK9 before it can bind the LDLR, evolocumab allows LDL receptors to be recycled back to the hepatocyte surface rather than degraded. More surface LDL receptors means greater hepatic clearance of LDL-C from the bloodstream. The PCSK9 receptor-recycling mechanism is described in the original characterization literature.

Clinical Efficacy Depends on Full Potency

Because evolocumab's mechanism is receptor-mediated and depends on achieving and maintaining adequate serum drug concentrations, any degradation that reduces binding affinity or accelerates clearance will blunt the LDL-C lowering effect. In the FOURIER trial (N=27,564), semaglutide and statins were not the comparators; rather, evolocumab added to statin therapy reduced LDL-C by a mean of 59% from baseline (from 92 mg/dL to 30 mg/dL) and reduced the primary MACE endpoint by 15% vs. Placebo (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). FOURIER, NEJM 2017

Achieving that 59% LDL-C reduction depends on injecting a fully active, properly stored product. A patient who unknowingly injects degraded drug may observe an attenuated LDL-C response on their next lipid panel, potentially prompting unnecessary dose escalation rather than recognition of a storage failure.

Half-Life and Dosing Frequency

Evolocumab has a terminal half-life of approximately 11 to 17 days following subcutaneous injection of the 140 mg dose, supporting either a 140 mg every-two-weeks or 420 mg once-monthly regimen. The Pushtronex on-body infusor delivers the 420 mg monthly dose as a subcutaneous infusion over approximately 9 minutes. Pharmacokinetic data from the Repatha prescribing information.

The extended dosing interval means patients frequently need to store product at home for two to four weeks between doses, making proper storage literacy a genuine clinical priority.

Dose-Form-Specific Storage Considerations

Not every Repatha presentation has identical handling characteristics. The differences between the SureClick autoinjector, the prefilled syringe, and the Pushtronex monthly cartridge affect practical storage decisions.

SureClick Autoinjector and Prefilled Syringe (140 mg/mL)

Both of these 140 mg presentations contain 1 mL of solution and share identical storage parameters: refrigerate at 2°C to 8°C, protect from light, do not freeze, do not shake, room-temperature use within 30 days. Patients should inspect the solution before each injection. The solution should be clear to opalescent, colorless to pale yellow, and free of visible particulates. Discoloration, cloudiness, or visible particles are signs of potential degradation and the product should not be injected. Injection site and product inspection guidance per FDA label.

Allow the autoinjector or syringe to reach room temperature for at least 30 minutes before injecting. Cold injections are not dangerous, but they are more uncomfortable and may cause patients to inject incompletely. The 30-minute warm-up does not affect the 30-day room-temperature countdown, provided the device was brought to room temperature specifically for that injection session.

Pushtronex On-Body Infusor (420 mg/3.5 mL)

The monthly 420 mg cartridge uses a larger volume and a different delivery mechanism. The same 2°C to 8°C refrigeration requirement applies. The cartridge should be removed from the refrigerator at least 45 minutes before use to allow full equilibration, given the larger volume. Once connected to the on-body infusor, the cartridge must be used immediately. Unused connected cartridges should be discarded. Pushtronex Instructions for Use, FDA label.

Shipping, Travel, and Cold-Chain Integrity

Specialty pharmacies ship Repatha in validated insulated containers with temperature-monitoring devices. These containers are typically validated to maintain 2°C to 8°C for 48 to 96 hours depending on ambient temperature and box design. Patients should unpack shipments immediately upon delivery and transfer the product to their refrigerator.

Traveling With Repatha

Air travel with biologic medications is governed by airline policies and TSA rules on liquids, but there is no federal prohibition on carrying Repatha in carry-on luggage. The TSA permits medically necessary liquids in quantities exceeding 3.4 oz when declared at screening. A letter from the prescriber explaining the medication and its refrigeration requirements is advisable for international travel.

For trips shorter than 30 days, patients may use an insulated cooler bag with a gel pack to keep the product below 25°C. Gel packs must not contact the autoinjector directly. Wrapping the device in a cloth inside the cooler prevents direct contact with ice and reduces freeze risk during cold weather travel.

For trips longer than 30 days, patients should arrange for local pharmacy dispensing at the destination or coordinate with their specialty pharmacy on advance shipment. Temperature management guidance for biologic medications is discussed in WHO cold-chain guidelines.

Temperature Excursion Documentation

Clinicians managing patients on PCSK9 inhibitors should ask about recent temperature excursions at every follow-up visit where an LDL-C result is lower than expected. A structured question, such as asking the patient to describe how they stored their last two pens, takes fewer than 30 seconds and may explain an otherwise puzzling LDL-C result. Medication adherence and storage errors in specialty biologics are discussed in this JAMA Network Open analysis.

Recognizing a Compromised Product: Visual and Contextual Clues

Protein aggregation can produce visible turbidity or particulate matter, but sub-visible aggregates (1 to 100 micrometers) are not detectable by eye. This means visual inspection alone is not a complete safeguard against degraded product. Contextual clues, specifically a documented temperature excursion or a missed dose of refrigeration, are equally important triggers for disposal decisions.

When to Discard Repatha

Discard the product immediately if any of the following apply.

The autoinjector or syringe shows visible particles, cloudiness, or discoloration.

The product has been frozen. Even if the solution appears normal after thawing, freeze-thaw damage is not reliably visible. Freeze-thaw impact on monoclonal antibody quality attributes.

The product has been at room temperature for more than 30 days.

The expiration date printed on the carton has passed.

The autoinjector or syringe has been dropped and the device integrity is in question.

Do not attempt to use a product that meets any of these criteria. Injecting degraded protein does not provide therapeutic benefit and carries a theoretical risk of injection-site reactions or systemic immunogenicity. Immunogenicity of degraded monoclonal antibodies.

How Proper Storage Connects to Cardiovascular Outcomes

The clinical stakes of proper evolocumab storage are not abstract. FOURIER demonstrated that LDL-C lowering with evolocumab produced a 20% reduction in the risk of myocardial infarction (HR 0.73, 95% CI 0.65 to 0.82) and a 21% reduction in stroke risk (HR 0.79, 95% CI 0.66 to 0.95) over a median follow-up of 2.2 years. FOURIER, NEJM 2017

Those outcomes were achieved with properly manufactured, properly stored, and correctly administered evolocumab. Post-FOURIER analyses, including the FOURIER-OLE open-label extension, showed continued cardiovascular benefit with longer-term treatment, with a 23% reduction in cardiovascular death, MI, or stroke in patients who received evolocumab for more than 5 years. FOURIER-OLE, Circulation 2023.

Attenuated LDL-C lowering from subpotent drug translates directly into attenuated event reduction. The relationship between LDL-C lowering and cardiovascular risk reduction is approximately log-linear across statin and non-statin therapies, as established by the Cholesterol Treatment Trialists Collaboration meta-analysis of 27 trials (N=174,149). For each 1 mmol/L (approximately 39 mg/dL) reduction in LDL-C, major vascular events are reduced by about 22%. CTT Collaboration, Lancet 2010.

A patient who injects degraded evolocumab and achieves only a 30% LDL-C reduction instead of 59% loses a meaningful fraction of the cardiovascular protection the drug was prescribed to provide.

Patient Education Checklist for Repatha Storage

Effective storage education reduces the rate of preventable product loss and ensures patients receive the full cardiovascular benefit of their prescription. The following framework can be delivered at the time of first prescription and reinforced at lipid panel follow-up visits.

At Prescription Initiation

Confirm the patient has a working refrigerator and can maintain a section between 2°C and 8°C. Patients in unstable housing situations may need a specialty pharmacy that dispenses in smaller quantities or offers refrigerator access support. Social determinants of medication adherence are addressed in AAFP guidance.

Instruct the patient to keep the product in its original carton at all times until the moment of injection. The carton provides light protection and makes the expiration date and dose visible.

Instruct the patient to write the date on the carton when removing it from the refrigerator if they plan to use room-temperature storage.

At Each Follow-Up Visit

Ask directly: "Where do you store your Repatha? Has it ever been left out overnight or left in a car?" These two questions identify the most common real-world excursion scenarios.

Review the LDL-C result in the context of the expected response. A reduction substantially below 50 to 60% from baseline, in the absence of dietary changes or drug interactions, should prompt a storage inquiry before any other intervention. LDL-C monitoring in PCSK9 inhibitor therapy per ACC/AHA 2018 guidelines.

Disposal and Waste

Expired or compromised Repatha should be disposed of through a drug take-back program or a sharps mail-back container. Do not flush biologics. The FDA's safe disposal guidance applies to all prescription medications. FDA drug disposal guidance.